



## Current Agreements

### Dealdoc

#### **Contract service agreement for BRCA1 and BRCA2 mutation testing for metastatic breast cancer study**

Myriad Genetics  
Abbott Laboratories  
Abbvie

Oct 27 2010

# Contract service agreement for BRCA1 and BRCA2 mutation testing for metastatic breast cancer study

<b>Companies:</b>	<a href="#">Myriad Genetics</a> <a href="#">Abbott Laboratories</a> <a href="#">Abbvie</a>
<b>Announcement date:</b>	Oct 27 2010
<b>Amendment date:</b>	Nov 03 2014
<b>Related contracts:</b>	<a href="#">Collaboration agreement for veliparib</a>

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

## Details

<b>Announcement date:</b>	Oct 27 2010
<b>Amendment date:</b>	Nov 03 2014
<b>Industry sectors:</b>	Bigpharma Diagnostic Pharmaceutical
<b>Therapy areas:</b>	Oncology » Breast cancer Diagnostics Diagnostics » Companion Discovery tools
<b>Technology types:</b>	Genomics Personalised medicine Pharmacogenomics Research services Screening
<b>Deal components:</b>	Contract service Evaluation

## Financials

## Termsheet

03 November 2014

Myriad Genetics has signed an expanded companion diagnostic agreement with AbbVie to use Tumor BRACAnalysis CDx as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

The collaboration builds upon Myriad's previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie's ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer.

---

27 October 2010

Myriad Genetics has signed an agreement with Abbott Laboratories to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.

This agreement is in addition to a similar previous agreement for a Phase II study with the same Study Drug.

Myriad will use its BRACAnalysis(R) test to identify the presence of germline mutations in the breast cancer patients to be enrolled in the Study.

Myriad will determine the mutation status of these patients and will provide standard test reports to the clinicians at each study site.

## Press Release

03 November 2014

Myriad Genetics, Inc. (MYGN) And AbbVie (ABBV) Sign Expanded Agreement For Tumor Bracanalysis CDx™

SALT LAKE CITY, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. (NYSE:ABBV), a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

The collaboration builds upon Myriad's previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie's ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer.

"Myriad's goal is to provide best-in-class patient care, and we believe that Tumor BRACAnalysis CDx will help us deliver on this goal by identifying patients who may respond to breakthrough therapies currently in development," said Peter Meldrum, president and CEO of Myriad. "We are excited to expand our collaboration with AbbVie, an emerging leader in oncology, and believe their choice of Myriad as a commercial partner speaks to our unique ability to provide high quality, high value companion diagnostic testing on a global basis."

About Tumor BRACAnalysis CDx™

Myriad's Tumor BRACAnalysis CDx is the most robust and accurate companion diagnostic test for identifying both germline (hereditary) and somatic (tumor) cancer-causing mutations in the BRCA1 and BRCA2 genes. Tumor BRACAnalysis CDx has undergone significant analytic validation and has been shown to identify up to 50 percent more patients with cancer-causing BRCA 1/2 mutations compared to germline testing alone. Myriad is actively collaborating with leading pharmaceutical companies to use Tumor BRACAnalysis CDx as a companion diagnostic with certain PARP inhibitors, platinum-based drugs and other chemotherapeutic agents. In the United States, the testing will be done at the Company's laboratory in Salt Lake City. In Europe, the CE-marked test will be performed at the Company's Munich laboratory.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: [www.myriad.com](http://www.myriad.com).

Myriad, the Myriad logo, BART, BRACAnalysis, Tumor BRACAnalysis CDx, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

---

27 October 2010

Myriad Genetics, Inc. (MYGN) and Abbott Laboratories (ABT) Enter Into Cooperative Agreement for Phase III Breast Cancer Study

27 October 2010

SALT LAKE CITY, Oct 26, 2010 (GlobeNewswire via COMTEX) -- Myriad Genetics, Inc. /quotes/comstock/15\*!mygn/quotes/nls/mygn (MYGN 19.86, -0.08, -0.40%) today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study (the "Study") of a novel drug candidate (the "Study Drug") for the treatment of metastatic breast cancer. This agreement is in addition to a similar previous agreement for a Phase II study with the same Study Drug.

Under the agreement, Myriad will use its BRACAnalysis(R) test to identify the presence of germline mutations in the breast cancer patients to be enrolled in the Study. Myriad will determine the mutation status of these patients and will provide standard test reports to the clinicians at each study site.

"We are extremely pleased to be working with Abbott, one of the world's leading healthcare companies, on this exciting new clinical study to find better, more effective treatments for patients suffering from breast cancer," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics."

#### About BRACAnalysis(R)

BRACAnalysis is an analysis of the BRCA1 and BRCA2 genes developed by Myriad Genetics for assessing a woman's risk for hereditary breast and ovarian cancer. A woman who tests positive with the BRACAnalysis test has, on average, an 82% risk of developing breast cancer during her lifetime and a 44% risk of developing ovarian cancer. BRACAnalysis provides important information that the Company believes will help patients and their physicians make better informed lifestyle, surveillance, preventive medication and treatment decisions. As published in the Journal of the National Cancer Institute, researchers have shown that pre-symptomatic individuals who have a high risk of developing breast cancer can reduce their risk by approximately 50% with appropriate preventive therapies. Additionally, as published in the New England Journal of Medicine, researchers have shown that pre-symptomatic individuals who carry gene mutations can lower their risk of developing ovarian cancer by approximately 60% with appropriate preventive therapies.

For more information about BRACAnalysis, please call 1-800-4-MYRIAD, or visit [www.myriadtests.com](http://www.myriadtests.com).

#### About Myriad Genetics

Myriad Genetics, Inc. is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products. Myriad's news and other information are available on the Company's Web site at [www.myriad.com](http://www.myriad.com).

The Myriad Genetics, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6336>

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

#### **Filing Data**

*Not available.*

#### **Contract**

*Not available.*